3 US Stocks Trading At An Estimated 16.4% To 35.6% Below Intrinsic Value

In This Article:

As the U.S. market continues to show resilience with major indices like the Dow Jones and S&P 500 on track for a winning month, investors are keenly observing how these trends impact stock valuations. In this environment, identifying undervalued stocks—those trading below their intrinsic value—can be a strategic move for those looking to capitalize on potential market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name

Current Price

Fair Value (Est)

Discount (Est)

Victory Capital Holdings (NasdaqGS:VCTR)

$72.03

$142.32

49.4%

NBT Bancorp (NasdaqGS:NBTB)

$50.08

$99.93

49.9%

UMB Financial (NasdaqGS:UMBF)

$126.05

$243.22

48.2%

West Bancorporation (NasdaqGS:WTBA)

$23.99

$46.83

48.8%

Five Star Bancorp (NasdaqGS:FSBC)

$33.16

$63.88

48.1%

Symbotic (NasdaqGM:SYM)

$23.995

$47.28

49.3%

Privia Health Group (NasdaqGS:PRVA)

$21.66

$43.17

49.8%

South Atlantic Bancshares (OTCPK:SABK)

$15.50

$30.26

48.8%

Intuitive Machines (NasdaqGM:LUNR)

$14.45

$28.66

49.6%

Snap (NYSE:SNAP)

$11.61

$22.76

49%

Click here to see the full list of 187 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of the screener.

Establishment Labs Holdings

Overview: Establishment Labs Holdings Inc. is a medical technology company that manufactures and markets medical devices for aesthetic and reconstructive plastic surgery, with a market cap of approximately $1.29 billion.

Operations: The company generates revenue primarily from its medical products segment, totaling $153.07 million.

Estimated Discount To Fair Value: 16.4%

Establishment Labs Holdings shows potential as an undervalued stock based on cash flows, trading at US$46.07, 16.4% below its estimated fair value of US$55.12. Despite recent volatility and shareholder dilution, the company's revenue is projected to grow significantly faster than the market at 23.6% annually, with earnings expected to rise sharply by over 49% per year. Recent FDA approval for innovative Motiva Implants could enhance future cash flow prospects despite current unprofitability forecasts over three years.

NasdaqCM:ESTA Discounted Cash Flow as at Nov 2024
NasdaqCM:ESTA Discounted Cash Flow as at Nov 2024

Bloomin' Brands

Overview: Bloomin' Brands, Inc. owns and operates a variety of dining restaurants ranging from casual to fine dining both in the United States and internationally, with a market cap of approximately $1.21 billion.

Operations: The company's revenue segments consist of $3.95 billion from the United States and $600.16 million from international operations.